ArcelorMittal reports second quarter 2026 results

ArcelorMittal (referred to as “ArcelorMittal” or the “Company” or the "Group") (MT (New York, Amsterdam, Paris, Luxembourg), MTS (Madrid)), the world’s leading integrated steel and mining company, announced results1 for the three-month and six-month periods ended June 30, 2026.

2Q 2026 key highlights:

Safety focus: Protecting employee health and safety is a core Company value. The multi-year safety transformation continues to deliver measurable improvements, with LTIF rate of 0.60x in 2Q'26.

Delivering structurally improved margins: The Group’s results continue to demonstrate resilience; 2Q 2026 EBITDA of $2.1bn, which represents a margin of $155/t, significantly higher than historical per tonne averages, reflecting the benefits of strategic investments, optimized assets and diversified market exposures. Europe EBITDA per tonne improved by $28/t sequentially, with further upside expected as the benefits of the new TRQ trade tool are realized. Net income in 2Q 2026 was $0.7bn (basic EPS of $0.90/sh).

Financial strength: After returning $0.6bn to shareholders and net working capital investment, net debt increased modestly compared with the prior quarter to $9.5bn4. Liquidity7 remains robust at $10.4bn, and the Company’s free cash flow outlook for 2026 and beyond remains unchanged.

Strong underlying cash generation, supporting shareholder returns and growth investment: The business generated $0.5bn of underlying free cash flow in 1H 2026, after investing $0.8bn in strategic growth projects and excluding the seasonal $2.0bn working capital investment. Given the positive prospects for 2H 2026 profitability, healthy cash generation in 2H 2026 should support continued returns to shareholders and lower net debt.

Capital return policy is creating significant value for shareholders: During 1H 2026, the Company returned

$0.7bn to shareholders ($0.2bn dividends and $0.5bn share buybacks). Following the partial monetization of its Vallourec stake, the proceeds of which have been allocated to share buybacks, shareholder returns in 2026 are expected to exceed the policy minimum (i.e. quarterly base dividend of $0.15/sh plus 50% of post-dividend FCF allocated to buybacks). The fully diluted share count has been reduced by 38% since September 20205.

 Strategic focus:

Positive outlook across the near, medium and long term: ArcelorMittal is well positioned to deliver value-accretive growth, with robust shareholder returns, whilst maintaining a strong investment-grade balance sheet. Our medium and long-term growth prospects are underpinned by a unique portfolio of opportunities. Alongside the next phase of our growth in India, the world's fastest-growing major steel market, the Company is currently reviewing potential downstream expansions in Brazil (leveraging our low-cost assets and long slab position), and further capacity growth in Liberia (leveraging existing infrastructure). Electrical steels is a core growth focus globally, with projects underway in the US and Europe, and opportunities under development in other key regions. We also see significant opportunities to further expand our renewable energy portfolio, generating more resilient, non-cyclical earnings while enhancing the competitiveness and sustainability of our steel business. Renewables is a key pillar of the Sustainable Solutions segment which remains on track to double its EBITDA by 2028 (vs. 2023).

 

 

 

 

Comments

Post a Comment

Popular posts from this blog

BPCL Dealer network launches “Fuelling the Festive Spirit” Campaign

Image
  Bharat Petroleum Corporation Limited (BPCL) dealer network has rolled out its festive season campaign, “Fuelling the Festive Spirit”, from 22nd September to 31st October 2025 across 3,000 Retail Outlets in Andhra Pradesh, Telangana, Karnataka, and Tamil Nadu.   Customers fuelling up with eligible transactions can win exciting prizes of 17 car and  83 Bikes through QR-based digital  slogan context participation. BPCL spokesperson said, “Festivals in India are a time of joy, giving, and togetherness. With ‘Fuelling the Festive Spirit,’ we are delighted to reward our customers and empower our frontline teams, making every visit to our retail outlets during this festive season truly memorable.”
Read more

Apollo Cancer Centers now introduces Made in India, CAR T Cell Program

Image
First Private Hospital in India to Successfully Complete CAR T Cell Therapy.  In a ground-breaking development, Apollo Cancer Centres (ACCs) has emerged as the first private hospital group in India to have a successfully complete CAR-T cell program and to further augment it, the group will now provide access to Made in India CAR-T cell therapy, beginning with NexCAR19 (Actalycabtagene autoleucel), for the treatment of B-cell lymphomas and B-acute lymphoblastic leukaemia in patients aged 15 years and above.   Marking a historic moment in the country's medical landscape , Dr. T Raja, Director of Medical Oncology at ACC, Chennai, spearheaded the development of this revolutionary clinical program, and has successfully treated six patients till date.   CAR-T cell therapies, often known as living drugs involve the extraction of a patients T-cells (a type of white blood cells whose function is to fight cancer cells) through a process known as Apheresis. These T-cells are t...
Read more

Gleneagles Hospital Successfully Treats Rare CNS (Brain) Lymphoma with Advanced CAR-T Cell Therapy

Image
Gleneagles Hospital Chennai, a part of Fortis Healthcare, has successfully treated a 49-year-old patient from Andhra Pradesh diagnosed with a rare and aggressive form of CNS(brain) lymphoma using advanced CAR-T cell therapy. Despite developing multiple serious treatment-related complications, the patient achieved complete remission and is doing well. The patient presented with complaints of persistent headache, giddiness, difficulty in walking, and weakness in his left arm and leg. Detailed investigations confirmed Primary Central Nervous System Lymphoma (PCNSL) , a rare type of lymphoma that affects the brain and is known to be difficult to treat. The patient initially received high-dose chemotherapy, the standard first-line treatment for this condition. However, the disease continued to progress despite four cycles of treatment. He subsequently underwent radiotherapy with chemotherapy, followed by oral targeted therapy as bridging treatment. As the lymphoma remained resistant to ...
Read more